FDA blasts California firm for multiple GLP issues involving nonclinical studies
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionBiologics/ biosimilars/ vaccinesEthicsNorth AmericaPreclinical studyRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchAudit/inspectionBiologics/ biosimilars/ vaccinesEthicsNorth AmericaPreclinical studyRegulatory Intelligence/Policy